The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Francis J. Giles

HRB Clinical Research Facilities

National University of Ireland Galway and Trinity College Dublin




Name/email consistency: high



  • HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College Dublin, Galway, Ireland. 2010 - 2013
  • Cancer Treatment and Research Center at The University of Texas Health Science Center, Institute for Drug Development, San Antonio, TX 78229, USA. 2009 - 2010
  • Professor of Medicine, and Chief, Division of Hematology and Medical Oncology, University of Texas Health Science Center at San Antonio, USA. 2008
  • The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, USA. 2007
  • Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA. 2001 - 2007
  • Division of Hematology and Medical Oncology, San Antonio, TX 78229, USA. 2007
  • M.D. Anderson Cancer Center, Department of Leukemia, The University of Texas, 1515 Holcombe Boulevard, USA. 2004
  • Section of Developmental Therapeutics, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, USA. 2002
  • The International Oncology Study Group, Houston, Texas 77401, USA. 2000


  1. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Giles, F.J., Swords, R.T., Nagler, A., Hochhaus, A., Ottmann, O.G., Rizzieri, D.A., Talpaz, M., Clark, J., Watson, P., Xiao, A., Zhao, B., Bergstrom, D., Le Coutre, P.D., Freedman, S.J., Cortes, J.E. Leukemia (2013) [Pubmed]
  2. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Giles, F.J., le Coutre, P.D., Pinilla-Ibarz, J., Larson, R.A., Gattermann, N., Ottmann, O.G., Hochhaus, A., Radich, J.P., Saglio, G., Hughes, T.P., Martinelli, G., Kim, D.W., Novick, S., Gillis, K., Fan, X., Cortes, J., Baccarani, M., Kantarjian, H.M. Leukemia (2013) [Pubmed]
  3. Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. Giles, F., Mahon, F.X., Gjertsen, B., Swords, R., Labar, B., Turkina, A., Rosti, G. Eur. J. Clin. Invest. (2012) [Pubmed]
  4. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Giles, F.J., Abruzzese, E., Rosti, G., Kim, D.W., Bhatia, R., Bosly, A., Goldberg, S., Kam, G.L., Jagasia, M., Mendrek, W., Fischer, T., Facon, T., Dünzinger, U., Marin, D., Mueller, M.C., Shou, Y., Gallagher, N.J., Larson, R.A., Mahon, F.X., Baccarani, M., Cortes, J., Kantarjian, H.M. Leukemia (2010) [Pubmed]
  5. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Giles, F.J., Rosti, G., Beris, P., Clark, R.E., le Coutre, P., Mahon, F.X., Steegmann, J.L., Valent, P., Saglio, G. Expert. Rev. Hematol (2010) [Pubmed]
  6. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Giles, F., Vey, N., DeAngelo, D., Seiter, K., Stock, W., Stuart, R., Boskovic, D., Pigneux, A., Tallman, M., Brandwein, J., Kell, J., Robak, T., Staib, P., Thomas, X., Cahill, A., Albitar, M., O'Brien, S. Blood (2009) [Pubmed]
  7. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Giles, F.J., O'Dwyer, M., Swords, R. Leukemia (2009) [Pubmed]
  8. New directions in the treatment of imatinib failure and/or resistance. Giles, F.J. Semin. Hematol. (2009) [Pubmed]
  9. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Giles, F.J., DeAngelo, D.J., Baccarani, M., Deininger, M., Guilhot, F., Hughes, T., Mauro, M., Radich, J., Ottmann, O., Cortes, J. Semin. Oncol. (2008) [Pubmed]
  10. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Giles, F.J., List, A.F., Carroll, M., Cortes, J.E., Valickas, J., Chen, B.L., Masson, E., Jacques, C., Laurent, D., Albitar, M., Feldman, E.J., Roboz, G.J. Leuk. Res. (2007) [Pubmed]
  11. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Giles, F.J., Borthakur, G., Ravandi, F., Faderl, S., Verstovsek, S., Thomas, D., Wierda, W., Ferrajoli, A., Kornblau, S., Pierce, S., Albitar, M., Cortes, J., Kantarjian, H. Br. J. Haematol. (2007) [Pubmed]
  12. Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML. Giles, F.J. Leuk. Lymphoma (2007) [Pubmed]
  13. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Giles, F.J., Cortes, J., Jones, D., Bergstrom, D., Kantarjian, H., Freedman, S.J. Blood (2007) [Pubmed]
  14. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. Giles, F., Rizzieri, D., Karp, J., Vey, N., Ravandi, F., Faderl, S., Khan, K.D., Verhoef, G., Wijermans, P., Advani, A., Roboz, G., Kantarjian, H., Bilgrami, S.F., Ferrant, A., Daenen, S.M., Karsten, V., Cahill, A., Albitar, M., Mufti, G., O'Brien, S. J. Clin. Oncol. (2007) [Pubmed]
  15. Plasma-based testing as a new paradigm for clinical testing in hematologic diseases. Giles, F.J., Albitar, M. Expert Rev. Mol. Diagn. (2007) [Pubmed]
  16. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Giles, F.J., Bellamy, W.T., Estrov, Z., O'Brien, S.M., Verstovsek, S., Ravandi, F., Beran, M., Bycott, P., Pithavala, Y., Steinfeldt, H., Reich, S.D., List, A.F., Yee, K.W. Leuk. Res. (2006) [Pubmed]
  17. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Giles, F., Verstovsek, S., Garcia-Manero, G., Thomas, D., Ravandi, F., Wierda, W., Ferrajoli, A., Kornblau, S., Jabbour, E., Shan, J., O'brien, S., Albitar, M., Kantarjian, H. Br. J. Haematol. (2006) [Pubmed]
  18. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Giles, F., Fischer, T., Cortes, J., Garcia-Manero, G., Beck, J., Ravandi, F., Masson, E., Rae, P., Laird, G., Sharma, S., Kantarjian, H., Dugan, M., Albitar, M., Bhalla, K. Clin. Cancer Res. (2006) [Pubmed]
  19. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Giles, F., Verstovsek, S., Thomas, D., Gerson, S., Cortes, J., Faderl, S., Ferrajoli, A., Ravandi, F., Kornblau, S., Garcia-Manero, G., Jabbour, E., O'Brien, S., Karsten, V., Cahill, A., Yee, K., Albitar, M., Sznol, M., Kantarjian, H. Clin. Cancer Res. (2005) [Pubmed]
  20. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Giles, F.J., Cortes, J.E., Kantarjian, H.M. Curr. Mol. Med. (2005) [Pubmed]
  21. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Giles, F.J., Tallman, M.S., Garcia-Manero, G., Cortes, J.E., Thomas, D.A., Wierda, W.G., Verstovsek, S., Hamilton, M., Barrett, E., Albitar, M., Kantarjian, H.M. Cancer (2004) [Pubmed]
  22. Novel therapies for patients with chronic myeloid leukemia. Giles, F.J., Kantarjian, H., Cortes, J. Expert. Rev. Anticancer. Ther (2004) [Pubmed]
  23. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Giles, F.J., Cortes, J.E., Kantarjian, H.M., O'Brien, S.M., Estey, E., Beran, M. Leuk. Res. (2004) [Pubmed]
  24. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Giles, F.J., Rodriguez, R., Weisdorf, D., Wingard, J.R., Martin, P.J., Fleming, T.R., Goldberg, S.L., Anaissie, E.J., Bolwell, B.J., Chao, N.J., Shea, T.C., Brunvand, M.M., Vaughan, W., Petersen, F., Schubert, M., Lazarus, H.M., Maziarz, R.T., Silverman, M., Beveridge, R.A., Redman, R., Pulliam, J.G., Devitt-Risse, P., Fuchs, H.J., Hurd, D.D. Leuk. Res. (2004) [Pubmed]
  25. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Giles, F.J., Faderl, S., Thomas, D.A., Cortes, J.E., Garcia-Manero, G., Douer, D., Levine, A.M., Koller, C.A., Jeha, S.S., O'Brien, S.M., Estey, E.H., Kantarjian, H.M. J. Clin. Oncol. (2003) [Pubmed]
  26. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Giles, F.J., Stopeck, A.T., Silverman, L.R., Lancet, J.E., Cooper, M.A., Hannah, A.L., Cherrington, J.M., O'Farrell, A.M., Yuen, H.A., Louie, S.G., Hong, W., Cortes, J.E., Verstovsek, S., Albitar, M., O'Brien, S.M., Kantarjian, H.M., Karp, J.E. Blood (2003) [Pubmed]
  27. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Giles, F.J., Cooper, M.A., Silverman, L., Karp, J.E., Lancet, J.E., Zangari, M., Shami, P.J., Khan, K.D., Hannah, A.L., Cherrington, J.M., Thomas, D.A., Garcia-Manero, G., Albitar, M., Kantarjian, H.M., Stopeck, A.T. Cancer (2003) [Pubmed]
  28. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. Giles, F.J., Kantarjian, H.M., Cortes, J.E., Garcia-Manero, G., Verstovsek, S., Faderl, S., Thomas, D.A., Ferrajoli, A., O'Brien, S., Wathen, J.K., Xiao, L.C., Berry, D.A., Estey, E.H. J. Clin. Oncol. (2003) [Pubmed]
  29. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Giles, F.J., Shi, G.G., Cortes, J.E., Thomas, D., Keating, A.R., Kantarjian, H.M., Keating, M.J., O'Brien, S.M. Cancer Chemother. Pharmacol. (2003) [Pubmed]
  30. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Giles, F.J., Miller, C.B., Hurd, D.D., Wingard, J.R., Fleming, T.R., Sonis, S.T., Bradford, W.Z., Pulliam, J.G., Anaissie, E.J., Beveridge, R.A., Brunvand, M.M., Martin, P.J. Leuk. Lymphoma (2003) [Pubmed]
  31. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Giles, F.J., Cortes, J.E., Halliburton, T.A., Mallard, S.J., Estey, E.H., Waddelow, T.A., Lim, J.T. Ann. Pharmacother (2003) [Pubmed]
  32. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Giles, F.J., Fracasso, P.M., Kantarjian, H.M., Cortes, J.E., Brown, R.A., Verstovsek, S., Alvarado, Y., Thomas, D.A., Faderl, S., Garcia-Manero, G., Wright, L.P., Samson, T., Cahill, A., Lambert, P., Plunkett, W., Sznol, M., DiPersio, J.F., Gandhi, V. Leuk. Res. (2003) [Pubmed]
  33. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Giles, F.J., Feldman, E.J., Roboz, G.J., Larson, R.A., Mamus, S.W., Cortes, J.E., Verstovsek, S., Faderl, S., Talpaz, M., Beran, M., Albitar, M., O'Brien, S.M., Kantarjian, H.M. Leuk. Res. (2003) [Pubmed]
  34. New drugs in acute myeloid leukemia. Giles, F.J. Curr. Oncol. Rep (2002) [Pubmed]
  35. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Giles, F.J., Kantarjian, H.M., Bekele, B.N., Cortes, J.E., Faderl, S., Thomas, D.A., Manshouri, T., Rogers, A., Keating, M.J., Talpaz, M., O'Brien, S., Albitar, M. Br. J. Haematol. (2002) [Pubmed]
  36. Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome. Giles, F., Garcia-Manero, G., O'Brien, S., Estey, E., Kantarjian, H. Acta Haematol. (2002) [Pubmed]
  37. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Giles, F.J. Expert. Rev. Anticancer. Ther (2002) [Pubmed]
  38. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. Giles, F.J., Cortes, J.E., Baker, S.D., Thomas, D.A., O'Brien, S., Smith, T.L., Beran, M., Bivins, C., Jolivet, J., Kantarjian, H.M. J. Clin. Oncol. (2001) [Pubmed]
  39. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. Giles, F.J., Wickham, N.R., Rapoport, B.L., Somlo, G., Lim, S.W., Shan, J., Lynott, A.M. Am. J. Hematol. (2000) [Pubmed]
  40. A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study. Giles, F.J., Shan, J., Chen, S., Advani, S.H., Supandiman, I., Aziz, Z., Caviles, A.P., Tee, G.Y., Chasen, M.R., Fahed, Z., Chaoj, T.Y., Aydogdu, I., Lynott, A.M. Leuk. Lymphoma (2000) [Pubmed]
  41. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study . Giles, F.J., Shan, J., Advani, S.H., Akan, H., Aydogdu, I., Aziz, Z., Azim, H.A., Bapsy, P.P., Buyukkececi, F., Chaimongkol, B., Chen, P.M., Cheong, S.K., Ferhanoglu, B., Hamza, R., Khalid, H.M., Intragumtornchai, T., Kim, S.W., Kim, S.Y., Koc, H., Kumar, L., Kumar, R., Lei, K.I., Lekhakula, A., Muthalib, A., Patel, M., Poovalingam, V.P., Prayoonwiwat, W., Rana, F., Reksodiputro, A.H., Ruff, P., Sagar, T.G., Schwarer, A.P., Song, H.S., Suh, C.W., Suharti, C., Supindiman, I., Tee, G.Y., Thamprasit, T., Villalon, A.H., Wickham, N.R., Wong, J.E., Yalcin, A., Jootar, S. Leuk. Lymphoma (2000) [Pubmed]
WikiGenes - Universities